Claims for Patent: 5,824,642

Summary for Patent: 5,824,642

Title:	Treatment of partial growth hormone insensitivity syndrome
Abstract:	Methods for increasing the growth rate of a human patient having partial growth hormone insensitivity syndrome, but not Laron syndrome, are described. One such method comprises administering an effective dose of growth hormone, preferably growth hormone with a native human sequence, with or without an N-terminal methionine, to the patient. The patient is characterized as having a height of less than about -2 standard deviations below normal for age and sex, a serum level of high-affinity growth hormone binding protein that is at least 2 standard deviations below normal levels, a serum level of IGF-I that is below normal mean levels, and a serum level of growth hormone that is at least normal. In another such method, the same patient population is treated with an effective amount of IGF-I, given alone or in combination with an amount of growth hormone that is effective in combination with the IGF-I.
Inventor(s):	Kenneth Attie, Lena M. S. Carlsson, Neil Gesundheit, Audrey Goddard
Assignee:	Genentech Inc
Application Number:	US08/468,580

Details for Patent 5,824,642

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ipsen Biopharmaceuticals, Inc.	INCRELEX	mecasermin	Injection	021839	August 30, 2005	5,824,642	2015-10-20